Tags : Hepatitis B

Janssen Collaborates with Arrowhead for the Initiation of REEF-1 P-IIB

Shots: Janssen to pay ~$25M milestone payments to Arrowhead with the onset of trial and has begun the dosing of patients in REEF-1(NCT03982186) P-IIB study involving assessing of JNJ-3989, JNJ-6379, NA, and/or PBO in 450 patients with chronic hepatitis B virus infection for 48 wks., evaluating its safety and efficacy Additionally, in Oct 2018 Arrowhead […]Read More

Gilead Signs an Exclusive Worldwide License Agreement with Durect for

Shots: Durect to receive $25M up front, ~$145M milestones including ~$75M for development & regulatory and ~$70M on sales plus royalties on sales of products. Gilead to get exclusive WW rights to develop and commercialize a long-acting injectable HIV product based on Durect’s SABER technology Gilead also has an exclusive right to access Durect’s SABER […]Read More